Therapy targeting the immune system's B cells might offer better odds against relapses in the early stages of multiple sclerosis (MS), a new study reports. People taking IV drugs that lower immune B-cell levels had a 62% lower rate of relapse than those taking pills frequently prescribed for early MS, the study team found.